Releases
Immutep Faces Class Action Over Alleged Efti Trial Misrepresentations
Investors who purchased Immutep Limited shares between March 24, 2025, and March 12, 2026, are being urged to join a class action lawsuit. The litigation alleges the company misled shareholders regarding the efficacy of its TACTI-004 clinical trial for the drug eftilagimod alfa.


















